Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 11/20 | 0.65 |
| ▸ | GABRP | O00591 | 2/20 | 0.48 |
| ▸ | GABRD | O14764 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRE | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.48 |
| ▸ | CPA1 | P15085 | 2/20 | 0.47 |
| ▸ | CPB1 | P15086 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5073961 | 0.81 | CPB2 (0.61) | CPB2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL5075309 | 0.80 | CPB2 (0.76) | CPB2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4009716 | 0.80 | CPB2 (0.75) | CPB2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4012774 | 0.79 | CPB2 (1.00) | CPB2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4005719 | 0.79 | CPB2 (1.00) | CPB2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4002365 | 0.79 | CPB2 (1.00) | CPB2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4509644 | 0.79 | CPB2 (0.65) | CPB2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL18057309 | 0.75 | CPB2 (0.68) | CPB2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL15314368 | 0.73 | CPB2 (0.63) | CPB2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4629770 | 0.73 | CPB2 (0.63) | CPB2GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | claimed |
| US-7423012-B2 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-7354895-B1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | LINSCHOTEN MARCEL | 2006-04-13 | — | — | US | disclosed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | disclosed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | disclosed |
| CN-1358187-A | New compounds | ASTRAZENECA AB (SE) | 2002-07-10 | — | — | CN | disclosed |
| EP-1180099-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066550-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | BPGM, PLG, FGB | CPB2 47/4885GABRP 162/4885GABRD 714/4885 |
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | CPN1, CPA1, DNPEP | CPB2 9/4885GABRP 2445/4885GABRD 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.